IDDF2018-ABS-0105 No resistance to TENOFOVIR ALAFENAMIDE detected through 96 weeks of treatment in patients with chronic hepatitis B
Sign Up to like & getrecommendations! Published in 2018 at "Gut"
DOI: 10.1136/gutjnl-2018-iddfabstracts.207
Abstract: Background Presented herein are the post Week 48 through Week 96 resistance analyses for 2 Phase 3 studies evaluating tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate(TDF) for the treatment of chronic hepatitis B (CHB) in… read more here.
Keywords: week; treatment; site substitutions; weeks treatment ... See more keywords